Why Did PolyPid Plunge 10.12% Despite Positive Trial Results?
On June 10, 2025, PolyPid's stock experienced a significant drop of 10.12% in pre-market trading.
Analysts from H.C. Wainwright have raised their price target for PolyPidPYPD-- to $13 from $11, maintaining a Buy rating on the shares. This adjustment reflects the company's promising developments and strategic initiatives.
Roth Capital has initiated coverage on PolyPid with a Buy rating and a $9 price target, highlighting the company's potential in the market. This bullish sentiment is supported by the successful Phase 3 trial results of D-PLEX100, which demonstrated a 58% reduction in surgical site infections.
The positive Phase 3 trial results for D-PLEX100 have been a significant driver for PolyPid's stock. The trial metMET-- all key secondary efficacy endpoints, showcasing the drug's effectiveness in preventing surgical site infections. This success positions D-PLEX100 as a strategic asset in addressing unmet medical needs, particularly in the surgical infection prevention sector.
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
Comments
No comments yet